The pharmaceutical industry is bracing for chaos if President Trump follows through on his threat to impose “a major tariff” ...

Plus: Comcast rolls out small-business assistance; Richie Neal takes Trump to task for tariff policies; Healey rolls out new ...

Treatment consisted of 4-6 cycles of dose-dense intensive chemotherapy incorporating hyperfractionated ...

AstraZeneca PLC closed 22.92% short of its 52-week high of £133.88, which the company reached on September 3rd.

AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...

AstraZeneca’s new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.

As first quarter earnings begin, executives are confronting market turmoil, regulatory instability and the threat of U.S.

Now may be an ideal time to buy stocks. Even if you don't have a lot of money that you can afford to invest, there are many ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

The US Food and Drug Administration (FDA) has approved AstraZeneca's human monoclonal antibody Imfinzi (durvalumab) with ...

The EC has approved Daiichi Sankyo and AstraZeneca’s Enhertu for use as a single agent to treat adults with certain breast ...

AstraZeneca PLC AZN shares dropped 6.96% to £100.56 Monday, on what proved to be an all-around dismal trading session for the ...